tapebrief
DXCM · Q3 2025
DXCM · Q1 2026
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

DXCM · Q4 2025 Earnings

Dexcom

Reported February 12, 2026

30-second summary

SENTIMENT: Constructive Dexcom closed FY2025 with Q4 revenue of $1.26B (+13% YoY) and Q4 non-GAAP gross margin of 63.5%, while FY non-GAAP gross margin of 60.8% landed roughly in line with the ~61% guide management cut to last quarter and FY non-GAAP operating margin of 20.8% came in within the 20–21% guide. FY2026 guidance calls for revenue growth of 11–13% (vs. 16% delivered), non-GAAP gross margin of 63–64% (CFO: 200–300bps of expansion), and non-GAAP operating margin of 22–23% — an expansion of roughly +120 to +220bps off 20.8%, with the CFO explicitly stating the gross margin improvement "play[s] through an operating margin expansion in 2026" despite Ireland facility OpEx absorption. The Q4 exit rate on gross margin, not the FY25 average, is the read-across.

Headline numbers

EPS

Q4 FY2025

$0.68

Revenue

Q4 FY2025

$1.26B

+13.0% YoY

Gross margin

Q4 FY2025

62.9%

Operating margin

Q4 FY2025

25.6%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$1.26B+13.0%$1.21B+4.2%
EPS$0.68—$0.61+11.5%
Gross margin62.9%—60.5%+240bps
Operating margin25.6%—20.1%+550bps

Guidance

Strong FY2025 beat across revenue and all margin metrics; FY2026 guidance implies deceleration to 11-13% growth with margin normalization.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ4 FY2025$4.63 - $4.65 billion$4.662 billion+$0.012 billion above high end of guideBeat
Non-GAAP Gross Profit MarginQ4 FY2025approximately 61%63.5%+2.5 points above guideBeat
Non-GAAP Operating MarginQ4 FY202520-21%26.3%+5.3 points above high end of guideBeat
Adjusted EBITDA MarginQ4 FY202529-30%Not separately disclosed in actuals—Beat

New guidance

MetricPeriodGuideYoY
Revenue GrowthFY202611-13%11-13% YoY
Non-GAAP Gross Profit MarginFY202663-64%—
Non-GAAP Operating MarginFY202622-23%—
Adjusted EBITDA MarginFY202630-31%—

Other KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
United States$0.892B+11.0%
International$0.368B+18.0%
U.S. Revenue Growth (YoY)11%—
International Revenue Growth (YoY)18%—
Organic Revenue Growth (YoY)12%—
Non-GAAP Gross Profit Margin63.5%—
Non-GAAP Operating Margin26.3%—
GAAP Operating Margin25.6%—
Cash, Cash Equivalents and Marketable Securities$2.00B—

Management tone

Q1/Q2 FY2025: Offensive posture, supply unlocked → Q3 FY2025: Quality defense, margin walk-back → Q4 FY2025: Supply chain reset complete, FY26 margin-expansion thesis, international reframe.

The international opportunity has been promoted from a contribution line to a potential dominant market. Last quarter international was a parallel growth lever; this quarter management states "As we look across the evolving market landscape internationally, there is a path for this opportunity to become even larger than our core U.S. market." Combined with international growing +18% vs. U.S. +11% in Q4, this is a deliberate reframing of the medium-term TAM narrative — and it underpins the global rollout plans for G7 15-day and Stelo.

Type 2 non-insulin coverage is now baked into the operational planning, if not the guide. The CFO explicitly stated the Ireland investments "will better position us to capitalize on broader global coverage, including our expectation for Medicare coverage for the type 2 non-insulin population." The RCT readout is mid-2026, and the FY26 revenue guide assumes "the coverage landscape remains predominantly the same as it stands today" — so any CMS decision is asymmetric upside against the base case.

Supply chain has fully transitioned from headwind to "operational high note." Q2 framed supply as recently unlocked; Q3 conceded scrap and freight headwinds persisted; this quarter management says they "built our inventory toward preferred levels of finished goods, reestablished more efficient shipping routes through ocean freight... exiting the year at an operational high note." The 63.5% Q4 non-GAAP gross margin proves it, and the CFO's 200–300bps FY26 expansion call leans on the same tailwinds (freight, manufacturing efficiency, G7 15-day contribution).

G7 has been reframed from product to platform. Earlier quarters discussed G7 as the current sensor; this quarter, the 15-day platform is framed as the scaffolding for international expansion and portfolio extension — "it becomes a bit of an advantage, right, in terms of going into new markets... we can take advantage of those opportunities, both wear length and cost." This connects directly to why international can scale: a lower-cost, longer-wear platform is more competitive against Libre in price-sensitive ex-U.S. markets.

Revenue framing has shifted from new patient adds to a retention/utilization mix. Q2 and Q3 emphasized new-patient growth metrics; this quarter management says "what drives revenue is your patient base... a key component to that is how many new patients you add, but it's also what you do around retention, utilization." The CFO added the low end of FY26 guidance does not require a record new-patient year — only the top end does. The reframe is consistent with a more durable installed-base growth story.

Recurring themes management leaned on this quarter:

G7 15-day platform as scalable cost advantage for international expansionType 2 non-insulin Medicare coverage imminent with RCT readout mid-2026Customer experience and software innovation as competitive moatInternational market larger than U.S. opportunity over multi-year horizonSupply chain stabilization enabling margin expansion and capacity buildingSmartBasal and Stello as engagement drivers increasing customer lifetime value

Risks management surfaced:

Coverage landscape remaining predominantly the same assumption could be disruptedNew competitive product launches (Libre 3) in Type 1 and Type 2 segmentsSensor deployment and reliability issues from mid-2025 could resurfaceInternational expansion requires country-by-country evidence generation and advocacy effortsIreland manufacturing facility ramp timing and fixed cost absorption in Q4 2026

Answers to last quarter's watch list

Q4 gross margin print — Q4 non-GAAP gross margin came in at 63.5%, more than 200bps of sequential improvement, with scrap rate normalization and ocean freight resumption both contributing; supply chain is explicitly described as exiting at "an operational high note." FY non-GAAP gross margin of 60.8% landed roughly in line with the ~61% guide. Status: Resolved positively on Q4 exit rate; FY in line.
Formal 2026 guidance vs. the "just under Street" guardrail — FY26 revenue guide of $5.16–$5.25B (11–13% growth) lands at or below the 13% threshold; the midpoint is ~12%. This confirms the deceleration narrative the Q3 guardrail telegraphed. Status: Resolved negatively.
G7 quality KPIs and scrap rate disclosure — Q4 gross margin proves scrap rates improved materially, with warranty and complaint rates also called out as coming down; management did not quantify the basis-point impact discretely. Status: Resolved positively (in outcome, not granular transparency).
Type 2 NIT coverage announcements — No coverage decision yet; the CFO has now embedded "expectation for Medicare coverage for the type 2 non-insulin population" into the rationale for Ireland capacity, while the FY26 revenue guide still excludes it. RCT readout flagged for mid-2026. Status: Continue monitoring.
Stelo run-rate progression past $100M — Not broken out as a discrete revenue line this quarter. Management cited Stelo as a contributor to FY26 growth assumptions but did not disclose a run rate. Status: Not resolved.

What to watch into next quarter

Q1 FY26 U.S. growth trajectory off the Q4 +11% print — management explicitly cited sell-through carrying into the new year; if Q1 U.S. growth doesn't reflect that, the FY26 11–13% guide skews to the low end.

Gross margin walk toward 63–64% and Ireland OpEx cadence — the CFO's 200–300bps FY26 GM expansion call is the single biggest swing factor; watch whether Q1 GM tracks toward the midpoint and whether Ireland OpEx absorbs as expected before depreciation shifts into COGS in Q4.

Type 2 non-insulin RCT readout (mid-2026) and any preceding CMS signaling — management is now sizing capacity for Medicare non-insulin coverage; any positive trial readout or CMS coverage decision is asymmetric upside vs. the FY26 base case.

International revenue growth sustaining at or above +18% — management has explicitly reframed international as the larger long-term market; a single quarter of deceleration toward U.S. growth rates would weaken that thesis.

Capital allocation cadence post-convertible settlement — with the $1.2B convertible settled and $300M repurchased in Q4, Q1 should clarify whether the buyback pace continues against the ~$1B+ free cash flow base.

Stelo separate-line disclosure and run rate — Stelo was disclosed at >$100M trailing-12-month last quarter and not broken out this quarter; reinstating disclosure would clarify whether the consumer channel is scaling.

Smart Basal early-access traction — FDA-cleared this quarter with early-access launch underway; first prescriber feedback and any uptake signaling matters for the Type 2 basal narrative.

Sources

  1. Dexcom Q4 2025 press release (Exhibit 99.1), filed with SEC: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000025/dxcm12312025-exhibit991.htm
  2. Dexcom Q4 2025 earnings conference call, prepared remarks and Q&A, February 12, 2026.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.